These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7353377)

  • 1. Unique effects of 24,25-dihydroxyvitamin D3 in uremic patients.
    Llach F; Brickman AS; Coburn JW
    Contrib Nephrol; 1980; 18():212-7. PubMed ID: 7353377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 25-hydroxy-vitamin D3 on intestinal absorption of calcium in normal man and patients with renal failure.
    Colodro IH; Brickman AS; Coburn JW; Osborn TW; Norman AW
    Metabolism; 1978 Jun; 27(6):745-53. PubMed ID: 651659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
    Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
    J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dihydroxylated metabolites of vitamin D3 on calcium absorption in uraemic man.
    Muirhead N; Catto GR; Gvozdanovic S; Gvozdanovic D; Edward N
    Clin Sci (Lond); 1981 Dec; 61(6):723-7. PubMed ID: 6975197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
    Baker LR; Muir JW; Cattell WR; Tucker KA; Sharman VL; Goodwin FJ; Marsh FP; Hately W; Morgan AG; de Saintonge DM
    Contrib Nephrol; 1980; 18():147-51. PubMed ID: 7353373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
    Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
    Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal phosphate absorption in normal and uremic man: effects of 1,25(OH)2-vitamin D3 and 1alpha(OH)-vitamin D3.
    Coburn JW; Brickman AS; Hartenbower DL; Norman AW
    Adv Exp Med Biol; 1977; 81():549-57. PubMed ID: 899939
    [No Abstract]   [Full Text] [Related]  

  • 11. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis.
    Berl T; Berns AS; Huffer WE; Alfrey AC; Arnaud CD; Schrier RR
    Contrib Nephrol; 1980; 18():72-81. PubMed ID: 6243528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intestinal absorption of Ca47 in chronic renal insufficiency before and after treatment with 1,25 dihydroxycholecalciferol].
    Vattimo A
    Minerva Med; 1979 Dec; 70(54):3705-7. PubMed ID: 523001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical importance of disorders of vitamin D metabolism].
    Flury W
    Schweiz Med Wochenschr; 1978 Jan; 108(4):129-33. PubMed ID: 341302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients.
    Peacock M; Davison AM; Walker GS
    Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologic effect of 1,24(R)(OH)2D3 versus 1,25(OH)2D3 administration in chronic renal failure.
    Coen G; Bondatti F; Donato G; Mazzaferro S; Pasquali M; Rosini S; Sardella D; Taggi F
    J Steroid Biochem Mol Biol; 1992 Sep; 42(8):823-9. PubMed ID: 1525043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of renal production of 24,25- and 1,25-dihydroxyvitamin D3 in young and adult rats by dietary calcium, phosphorus, and 1,25-dihydroxyvitamin D3.
    Armbrecht HJ; Zenser TV; Davis BB
    Endocrinology; 1982 Jun; 110(6):1983-8. PubMed ID: 6978809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
    Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
    Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.